Eli Lilly and Company $LLY Shares Acquired by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 213,986 shares of the company’s stock after acquiring an additional 11,817 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Eli Lilly and Company were worth $228,151,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LLY. 10Elms LLP lifted its position in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares in the last quarter. Bridgewater Advisors Inc. grew its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after purchasing an additional 11 shares in the last quarter. Manske Wealth Management increased its stake in Eli Lilly and Company by 2.5% during the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after buying an additional 11 shares during the period. Guardian Partners Inc. lifted its holdings in Eli Lilly and Company by 0.3% in the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after buying an additional 12 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL boosted its position in Eli Lilly and Company by 1.6% in the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock valued at $565,000 after buying an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.4%

Shares of LLY stock opened at $910.59 on Tuesday. The stock has a fifty day moving average of $1,019.76 and a two-hundred day moving average of $960.48. The firm has a market capitalization of $860.34 billion, a PE ratio of 39.68, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on LLY shares. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 target price for the company. CICC Research lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a report on Wednesday, February 11th. Barclays assumed coverage on shares of Eli Lilly and Company in a research report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price target for the company. Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,221.44.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly expanded access for its weight?loss drug Zepbound by launching a self?pay option (starting at $299/month for the low dose) through LillyDirect and major pharmacies — a move that should broaden the addressable market and help revenue growth if uptake scales. Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook
• Positive Sentiment: Analysts continue to point to upside after Lilly’s strong February quarter (revenue and EPS beats and raised FY guidance); several pieces highlight upgraded price targets and room for further appreciation based on product momentum. Here’s How Much Upside Eli Lilly Stock Has, According to Analysts
• Neutral Sentiment: Lilly’s leadership joined other U.S. CEOs at the China Development Forum and signaled renewed investment in China; management interest supports long?term expansion but geopolitical uncertainty keeps execution risk elevated. U.S. executives, from Apple to Eli Lilly, revamp their push into the world’s second-largest economy at the China Development Forum
• Neutral Sentiment: Local planning discussions about a proposed Eli Lilly plant in Lehigh Valley signal capacity expansion plans that could support manufacturing scale — watch for permitting/timeline news that would affect capital expenditure and supply. Lehigh Valley planners to discuss traffic, other potential issues with proposed Eli Lilly plant
• Neutral Sentiment: Market commentary flags an upcoming April 10 event described as a “make?or?break” test versus rival Novo Nordisk — this creates short?term binary risk around competitive positioning in obesity/GLP?1 markets. Eli Lilly Stock (LLY) Faces This Make-or-Break Test on April 10
• Negative Sentiment: Benzinga and other outlets note the U.S. Supreme Court revived Actos litigation exposure — renewed legal risk could create headline volatility and potential liabilities. What’s Going On With Eli Lilly On Monday?
• Neutral Sentiment: “Should you buy before April 10?” pieces are framing short?term timing decisions for investors; they reiterate the same balance of strong fundamentals versus near?term competitive and legal catalysts. Should You Buy Eli Lilly Stock Before April 10?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.